Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Purpose: Evasion from chemotherapy-induced apoptosis due to p53 loss strongly contributes to drug resistance. Identification of specific targets for the treatment of drug-resistant p53-null tumors would therefore increase the effectiveness of cancer therapy. Experimental Design: By using a kinase-directed short hairpin RNA library and HCT116p53KO drug-resistant colon carcinoma cells, glycogen synthase kinase 3 beta (GSK3B) was identified as a target whose silencing bypasses drug resistance due to loss of p53. p53-null colon cancer cell lines with different sets of mutations were used to validate the role of GSK3B in sustaining resistance and to characterize cell death mechanisms triggered by chemotherapy when GSK3B is silenced. In vivo xenograft studies were conducted to confirm resensitization of drug-resistant cells to chemotherapy upon GSK3 inhibition. Colon cancer samples from a cohort of 50 chemotherapy-treated stage II patients were analyzed for active GSK3B expression. Results: Downregulation of GSK3B in various drug-resistant p53-null colon cancer cell lines abolished cell viability and colony growth after drug addition without affecting cell proliferation or cell cycle in untreated cells. Cell death of 5-fluorouracil (5FU)–treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis. In vivo studies showed that drug-resistant xenograft tumor mass was significantly reduced only when 5FU was given after GSK3B inhibition. Tissue microarray analysis of colon carcinoma samples from 5FU-treated patients revealed that GSK3B is significantly more activated in drug-resistant versus responsive patients. Conclusions: Targeting GSK3B, in combination with chemotherapy, may represent a novel strategy for the treatment of chemotherapy-resistant tumors. Clin Cancer Res; 19(14); 3820–31. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · cited 1×
“Poor specificity is due to the fact that "classical" chemotherapeutic drugs act by inducing a generic damage (either to the DNA or the microtubuli) that cells recognize as an apoptotic trigger (1).”
BackgroundIdentification of RIP1 kinase as a specific cellular target of necrostatins
Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.83 · Cited by 2,059
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 2×
“Based on these premises, we conducted a phenotype screen using the kinase pools of the NKI short hairpin RNA (shRNA) library (7) and 5-fluorouracil (5FU)-resistant HCT116p53KO cells (8) as a model.”
BackgroundMethodHypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894 · cited 1×
“Moreover, they often directly or indirectly contribute to render cancer cells more resistant to different types of stress (5, 6).”
BackgroundThe Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis
Vandenabeele, P., Declercq, W., Van Herreweghe, F., & Vanden Berghe, T. (2010) · Science Signaling · doi:10.1126/scisignal.3115re4 · Cited by 482 · cited 1×
“RIP1 has been shown to mediate necroptosis in response to TNF receptor engagement (43), radiations (44), a few drugs (45) and so far its activation is thought to be central for the modulation of the necroptotic response.”
BackgroundNuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling
Hong, S. J., Dawson, T. M., & Dawson, V. L. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.005 · Cited by 463 · cited 1×
“Once liberated in the cytosol tAIF translocates to the nucleus, where it promotes large-scale fragmentation ofDNA,peripheral chromatin condensation, and, ultimately, cytotoxicity (22).”
BackgroundGlycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L. (2008) · Nature · doi:10.1038/nature07284 · Cited by 265
Cited by
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0636 · Cited by 335
GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer
Lin, J., Song, T., Li, C., & Mao, W. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118659 · Cited by 268
MicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer
Zhang, Y., Geng, L., Talmon, G., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620252 · Cited by 100
“p53 has been implicated to contribute to 5-FU- and other chemotherapeutic drug-induced apoptosis, which involves the DNA damage response (18, 37).”
BackgroundMicroRNA-224 sustains Wnt/β-catenin signaling and promotes aggressive phenotype of colorectal cancer
Li, T., Lai, Q., Wang, S., Cai, J., Xiao, Z., Deng, D., He, L., Jiao, H., Ye, Y., Liang, L., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0287-1 · Cited by 92
Romano, G., Santi, L., Bianco, M. R., Giuffrè, M. R., Pettinato, M., Bugarin, C., Garanzini, C., Savarese, L., Leoni, S., Cerrito, M. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7895 · Cited by 66
Self-citation
Metadata
- Authors
- Grassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., Masiero, L., Leone, B. E., Bonin, S., Donada, M., Stanta, G., Helin, K., & Lavitrano, M.
- Venue
- Clinical Cancer Research
- Published
- 2013-07-15
- Volume
- 19
- Issue
- 14
- Pages
- 3820-3831
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2135794202
- Cited by
- 93
- References
- 11
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3289
- The paper
- Grassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., Masiero, L., Leone, B. E., Bonin, S., Donada, M., Stanta, G., Helin, K., & Lavitrano, M. (2013). Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.